化疗对转移性结直肠癌的乘客突变的影响
Marium T Siddiqui1, Matthew A Cottam1, Muhammad Bilal Mirza1
1Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Molecular oncology
|November 5, 2025
概括
化疗可以减少转移性结直肠癌 (mCRC) 的乘客突变,特别是在微卫星稳定 (MSS) 病例中. 这一发现表明,乘客突变和瘤突变负担 (TMB) 可以指导MSS mCRC.的未来治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 癌症研究 癌症研究
背景情况:
- 转移性结直肠癌 (mCRC),特别是微卫星稳定 (MSS) 亚型,对免疫治疗的反应有限.
- 化疗是mCRC的主要治疗方法,但其对瘤更广泛的突变格局的影响尚不清楚.
- 乘客突变,一旦被认为是惰性的,可能与瘤突变负担 (TMB) 和影响治疗结果相关.
研究的目的:
- 研究化疗对转移性结直肠癌 (mCRC) 乘客突变的影响.
- 探索乘客突变,瘤突变负担 (TMB) 和mCRC中的治疗反应之间的关系.
- 评估乘客突变模式作为生物标志物的潜力,以指导MSS mCRC中的治疗决策.
主要方法:
- 来自22名mCRC患者的原发性和转移性瘤样本的整体外基因组测序.
- 对驱动突变 (APC,KRAS,TP53) 和乘客突变的分析,特别是在Titin (TTN) 等大型基因中.
- 化学疗法治疗样本与化疗治疗样本中的突变特征的比较.
主要成果:
- 在APC,KRAS和TP53.3中一致观察到反复发生的驱动突变.
- 大基因的乘客突变,特别是TTN,在化学无效样本中得到了丰富,并与更高的TMB相关.
- 化疗治疗导致乘客突变的显著减少,这表明过度突变亚克隆的选择性耗尽.
结论:
- 化疗可以选择性地减少mCRC的乘客突变,可能会影响高突变亚克隆的持久性.
- 乘客突变模式和TMB可以作为预测mCRC治疗反应的宝贵生物标志物.
- 这些发现表明,乘客突变在指导MSS mCRC患者免疫治疗决策方面可能发挥作用.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Mismatch Repair
6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


